BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
1.670
-0.090 (-5.11%)
At close: Feb 27, 2026, 4:00 PM EST
1.650
-0.020 (-1.20%)
After-hours: Feb 27, 2026, 7:40 PM EST

BioXcel Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Feb '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
3719866025691,126
Market Cap Growth
319.02%-78.51%-85.65%5.82%-49.47%327.27%
Enterprise Value
1108396462317895
Last Close Price
1.675.9847.20343.68325.28739.20
PS Ratio
48.578.1962.581605.17--
PB Ratio
--0.20-1.537.842.575.45
P/TBV Ratio
---7.842.575.45
EV/Sales Ratio
145.7936.6969.821233.33--
Debt / Equity Ratio
-1.23-1.11-1.791.220.010.01
Net Debt / Equity Ratio
-0.82-0.78-0.63-1.30-1.05-1.02
Net Debt / EBITDA Ratio
-1.46-1.13-0.210.632.172.58
Net Debt / FCF Ratio
-1.26-1.01-0.230.742.813.18
Asset Turnover
0.020.040.010.00--
Inventory Turnover
0.971.610.63---
Quick Ratio
0.961.352.405.9013.9818.00
Current Ratio
1.181.682.656.1714.2118.33
Return on Equity (ROE)
---1766.94%-111.08%-49.93%-70.35%
Return on Assets (ROA)
-67.31%-72.30%-74.95%-44.81%-29.10%-40.13%
Return on Capital Employed (ROCE)
-721.90%-402.40%-361.00%-92.30%-48.00%-39.50%
Earnings Yield
-186.77%-321.18%-207.35%-27.54%-18.80%-7.30%
FCF Yield
-159.39%-388.15%-179.52%-22.51%-14.52%-5.92%
Buyback Yield / Dilution
-235.79%-39.21%-4.00%-6.23%-21.63%-33.11%
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q